摘要:
Isoindole compounds of the formula (I) ##STR1## wherein R.sub.1 represents hydrogen; C.sub.1 -C.sub.6 alkyl; benzyl optionally substituted with halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, methylenedioxy; C.sub.2 -C.sub.8 aliphatic acyl; benzoyl optionally substituted with halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.2 -C.sub.6 alkanoyl, C.sub.2 -C.sub.6 alkanoyloxy, C.sub.1 -C.sub.4 alkyl, trifluoromethyl, methylenedioxy;R.sub.2 -R.sub.3 are selected independently from hydrogen; halogen; C.sub.1 -C.sub.4 alkyl; trifluoromethyl; hydroxy; nitro; amino; mono or di C.sub.1 -C.sub.4 alkylamino; cyano; C.sub.1 -C.sub.6 alkoxy; C.sub.2 -C.sub.6 alkoxycarbonyl;Y is ethylene, or a straight or branched alkylene chain containing from 3 to 6 carbon atoms, and the salts thereof of pharmaceutically acceptable acids. The compounds possess antianginal activity and are used in the preparation of medicaments for antianginal therapy.
摘要:
##STR1## Compounds of formula (I) wherein X, Y, R 1 and R 2 have the meanings specified in the specification, are endowed with cardiovascular activity.
摘要:
##STR1## Compounds of formula (I) wherein X, Y, R 1 and R 2 have the meanings specified in the specification, are endowed with cardiovascular activity.
摘要:
Benzoxazinone and benzothiazinone derivatives of formula ##STR1## wherein R represents hydrogen, (C.sub.2-6)alkyl, (C.sub.5-7)cycloalkyl, phenyl, substituted phenyl; R.sub.1 and R.sub.2 independently represents hydrogen, halogen, (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy or trifluoromethyl; X is oxygen or sulfur; Y is (C.sub.2-6)alkylene or (C.sub.5-7)cycloalkylene; and salts therewith of pharmaceutically acceptable acids. The compounds possess cardiovascular activity with high specificity for the coronary district.